Clinical Trials Logo

Filter by:
NCT ID: NCT06194669 Recruiting - Clinical trials for Carcinoma, Renal Cell

Mechanisms of Somatic Mutation and Tumor Initiation in Pre-malignant Kidney Tubule Cells

SoMuKT
Start date: June 30, 2023
Phase:
Study type: Observational

The goal of this observational study is to analyze somatic mutations in the genome of normal kidney cells from patients affected by kidney cancer predisposition syndrome Von Hippel Lindau (VHL) and compare the mutation rates observed in these patients and in individuals not affected by the disease. The main questions the study aims to answer are: - Do kidney cells from VHL patients mutate more than cells from control individuals during adult life? - What mechanisms favor somatic mutation occurrence in the genome of normal kidney tubule cells? Participants will donate one blood sample and multiple urine samples. Urines will be used for kidney cell isolation, followed by cell culturing and genetic analyses. Urine samples will be collected once a year for 3-5 years. Sample collection will occur during the yearly screening program that each patient undergoes at the hospital. In case patients undergo surgical treatment of kidney tumors, samples discarded from surgery (tumor and normal kidney adjacent to tumor) will be collected and subjected to genetic analyses. Researchers will compare the number and types of mutations found in tumors and normal kidney cells from VHL-disease patients with those found in normal kidney cells from control individuals, to see if somatic mutation rates are increased in VHL-disease patients during aging.

NCT ID: NCT06193850 Recruiting - Urologic Diseases Clinical Trials

Protocol N. 2014 - Observational Study on the Quality of Life of Outpatients

Start date: February 24, 2015
Phase:
Study type: Observational

Prospective observational study on the quality of life of patients attending general urology, sexual medicine, reproductive medicine, functional urology, neuro-urology and uro-oncology clinics.The data relating to the clinical conditions (disease state, psychological and related to quality of life) of the patients belonging to the above-mentioned clinics will be collected in a specially designed database which will allow us to extract the data in a simple and safe way used for statistical analyses. in clinical research.

NCT ID: NCT06193642 Recruiting - Clinical trials for Osteogenesis Imperfecta

Increasing Knowledge on Osteogenesis Imperfecta by Collecting Epidemiological Data

4FRAILTY
Start date: January 20, 2023
Phase: N/A
Study type: Interventional

interventional pilot study with the enrollment of patients affected by Osteogenesis Imperfecta

NCT ID: NCT06193616 Recruiting - Clinical trials for Autosomal Dominant Polycystic Kidney

Outcome of ADPKD With Octreotide LAR

ADPKD648
Start date: February 12, 2024
Phase:
Study type: Observational

In this observational, retrospective study we will primarily aim at evaluating the independent role of baseline clinical and laboratory parameters, including TKV, in the prediction of long term chronic GFR decline and other clinical outcomes and, secondarily, the relationships between GFR and TKV changes over time, in a cohort of ADPKD patients with Stage IV CKD on chronic treatment with octreotide LAR and routinely monitored with serial GFR, TKV and clinical evaluations, at the outpatient clinic of the Nephrology Unit of the Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy.

NCT ID: NCT06193577 Recruiting - Weight Loss Clinical Trials

Effect of Phaseolus Vulgaris L. Dry Extract on the Modulation of Weight and Metabolic Parameters

Start date: November 8, 2023
Phase: N/A
Study type: Interventional

Evaluation of the efficacy of Phaseolus vulgaris L. dry extract on weight modulation.

NCT ID: NCT06193200 Recruiting - Clinical trials for Ataxia Telangiectasia

To Evaluate the Effects of EryDex in Patients With A-T

NEAT
Start date: June 2024
Phase: Phase 3
Study type: Interventional

This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of EryDex (dexamethasone sodium phosphate [DSP] in autologous erythrocytes), administered by intravenous (IV) infusion once every 28 days, on neurological symptoms of patients with Ataxia Telangectasia (A-T).

NCT ID: NCT06193057 Recruiting - Clinical trials for Ankle Osteoarthritis

Comparison of Customized and Standard Total Ankle Prostheses

Start date: July 26, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to compare primary total ankle replacement (TAR) performed with a customized procedure (prostheses customized for each patient based on his or her ankle morphology reconstructed from tomographic scans, and implanted via cutting guides customized for the patient) with standard primary TARs, considering: objective radiological results, subjective patient outcomes, and overall costs of both procedures

NCT ID: NCT06193018 Recruiting - Clinical trials for Occupational Exposure

Ergonomic Effects of Using a Professional Passive Exoskeleton

Start date: May 10, 2023
Phase:
Study type: Observational

Work-related musculoskeletal disorders (WRMSD), multifactorial diseases that affect the working population and which can be caused and/or aggravated by work and occupational exposures, continue to Prevention interventions for these pathologies have recently made use of technological advancement, which has made external devices available for the assistance of human activities, i.e. occupational exoskeletons (EXO). Despite the suggestive potential inherent in these devices, their actual adoption in the working and industrial world is still uncertain due to the absence of evidence on their effectiveness, safety of use and appropriateness. The use of EXO increases the user's ability to carry out manual tasks in different work contexts, lightening the perception of physical effort and promoting higher levels of safety, as well as promoting better performance. These advantages derive from the effective reduction in muscle activity that the use of EXO allows. A certain variability in the effects was referred to factors such as the type of work task, the type of exoskeleton adopted, the duration of use of the exoskeleton, as well as to individual differences and different behaviours at work. The field studies, carried out so far in the automotive, manufacturing, logistics and agriculture sectors, are fundamental to understanding the actual effectiveness, practicality, safety and acceptance of EXO by the user. This project contributes to the expansion of knowledge relating to the prevention of WRMSD through EXO, applying wearable sensors in a real working situation such as the textile sector, in which the female gender constitutes the majority of the workforce.

NCT ID: NCT06192563 Recruiting - Dermatitis Atopic Clinical Trials

A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment

AD-BEASCUITS
Start date: November 30, 2023
Phase:
Study type: Observational

In adolescents treated with dupilumab, clinical trials showed significant improvement of atopic dermatitis (AD) signs and symptoms, with a good safety profile. In these clinical trials, only patients with Eczema Area and Severity Index (EASI) score greater than or equal to (≥) 16 were enrolled, and effectiveness on sensitive/visible areas was not specifically evaluated. Further data about the effectiveness of dupilumab in adolescent participants with moderate to mild EASI score and severe itching and/or localized AD are therefore necessary to better understand the potential clinical benefits of dupilumab in these populations. This is an Italian multicenter, 52-week observational (non-interventional) study which will collect data on the characteristics of adolescent (aged 12 to 17 years) participants who suffer from severe AD with EASI score less than (<) 16, eligible for systemic dupilumab treatment according to Italian reimbursement criteria. It will study the real-world effectiveness and safety of dupilumab in this population, the effect of dupilumab on itching (pruritus), sleep, quality of life and related outcomes, localized AD in sensitive/visible areas, and on coexisting atopic conditions in adolescent participants who receive dupilumab for AD. It will also document dupilumab treatment satisfaction and dupilumab discontinuation in the study participants.

NCT ID: NCT06192524 Recruiting - Heart Failure Clinical Trials

OPTImal PHARMacological Therapy for Patients With Heart Failure: The OPTIPHARM-HF Registry

OPTIPHARM-HF
Start date: July 18, 2022
Phase:
Study type: Observational [Patient Registry]

Prospective, observational, multicenter, national study of adult patients with HF to assess prescription and adherence to evidence-based Guideline-Directed Medical Therapy (GDMT) in patients with Heart Failure (HF).